Percutaneous left atrial appendage closure using 
the LAmbre device. First clinical results in Poland

Burysz, Marian; Litwinowicz, Radosław; Bryndza, Magdalena; Skowronek, Radomir; Ogorzeja, Wojciech; Bartuś, Krzysztof

doi:10.5114/aic.2019.86019

Cited by 11 publications

(15 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with the registries of the Watchman™ and Amplatzer Amulet™ devices, the present study shows a higher percentage of patients with chronic kidney disease and with higher CHA 2 DS 2 -VASc and HAS-BLED scores [ 7 , 8 , 17 , 18 , 19 ]. In comparison with previous studies of the LAmbre™ system [ 10 , 11 , 12 , 14 ], this registry shows the same profile of high-complexity patients, although with higher CHA 2 DS 2 -VASc and HAS-BLED scores. The immediate results with this device are notable (100% device success) and in line with the few existing registries of LAAC with the LAmbre™ thus far published, with device success rates from 99.4% to 100% and procedural success rates from 92% to 99.4% [ 10 , 11 , 12 , 14 ].…”

Section: Discussionsupporting

confidence: 64%

“…In comparison with previous studies of the LAmbre™ system [ 10 , 11 , 12 , 14 ], this registry shows the same profile of high-complexity patients, although with higher CHA 2 DS 2 -VASc and HAS-BLED scores. The immediate results with this device are notable (100% device success) and in line with the few existing registries of LAAC with the LAmbre™ thus far published, with device success rates from 99.4% to 100% and procedural success rates from 92% to 99.4% [ 10 , 11 , 12 , 14 ].…”

Section: Discussionsupporting

confidence: 64%

“…The LAmbre™ system (Lifetech Scientific, Shenzhen, China) is a new self-expanding and recapturable device specifically designed for LAAC including complex morphology. The first registries with the LAmbre™ showed a high device implantation success rate and remarkable short-term performance in terms of stroke prevention [ 10 , 11 , 12 , 13 ]. Nonetheless, the mid-term clinical data for this device are still limited.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Left Atrial Appendage Closure with a New Occluder Device: Efficacy, Safety and Mid-Term Performance

Llagostera-Martín

Cubero-Gallego

Mas‐Stachurska

et al. 2021

JCM

View full text Add to dashboard Cite

The LAmbreTM device is a novel system designed for left atrial appendage closure (LAAC). First registries showed a high rate of device implantation success. However, few mid-term results are available. We present our 1- and 12-month follow-up results for this device. This prospective, single-center registry included consecutive patients with nonvalvular atrial fibrillation who underwent LAAC with the LAmbreTM device. Transesophageal echocardiography (TEE) was performed at 1-month follow-up. In total, 55 patients were included. The population was elderly (75 ± 9.4 years), with a high proportion of comorbidities. The mean CHA2DS2-VASc and HAS-BLED scores were 4.6 ± 1.6 and 3.9 ± 1.0, respectively. Previous history of a major bleeding event was present in 37 patients (67.3%). Procedural success was achieved in 54 patients (98.2%). Device success was achieved in 100% of patients in whom device implantation was attempted (54 patients). Major in-hospital device-related complications included mortality of one patient (1.8%) and pericardial tamponade in two patients (3.6%); the incidence of stroke was 0%. No thrombus or significant leaks (≥5 mm) were observed on 1-month TEE. At 12 months, adverse events were overall death (1.8%), transient ischemic attack/ischemic stroke (1.8%), and major bleeding events (Bleeding Academic Research Consortium (BARC) 3a and 3c; 11%). In this high-risk population, the LAmbreTM device seems to be a safe and effective option for LAAC with a remarkable mid-term performance.

show abstract

Section: Discussionsupporting

confidence: 64%

Section: Discussionsupporting

confidence: 64%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Left Atrial Appendage Closure with a New Occluder Device: Efficacy, Safety and Mid-Term Performance

Llagostera-Martín

Cubero-Gallego

Mas‐Stachurska

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Patient selection was in accordance with the guidelines 8 . Inclusion and exclusion criteria for Amulet and LAmbre endocardial LAAO procedure, 9 as well as Lariat epicardial LAAO procedure have been described previously 10 . In both centers, a team of two cardiac surgeons, who underwent training using a simulation model, performed the procedures.…”

Section: Methodsmentioning

confidence: 99%

Why should cardiac surgeons occlude the left atrial appendage percutaneously?

Litwinowicz

Mazur

Burysz³

et al. 2020

J Card Surg

Self Cite

View full text Add to dashboard Cite

Objectives: Percutaneous left atrial appendage (LAA) occlusion (LAAO) is a procedure dominated by cardiologists. The aim of our study was to present the results of percutaneous LAAO performed solely by cardiac surgeons. Methods: Two hundred twenty-three consecutive patients with nonvalvular atrial fibrillation underwent percutaneous LAAO in two cardiac surgery sites. In the first center, all 84 LAAO procedures were performed with the endocardial LAA occluders: 60 cases with the Amulet and 24 cases with the LAmbre. In the second center, all 139 LAAO procedures were performed with the LARIAT epicardial device. Results: The mean CHA 2 DS 2-VASc-score was 3.7 ± 1.8 points, and mean HAS-BLED score was 3.6 ± 1.2 points. The procedure was successful in 97.3% of cases. Procedural or device-related adverse events were noted in 4.4% (n = 10) of cases: one periprocedural cardiac arrest, one aortic injury, one gastrointestinal bleeding, three cases of vascular access complications, and four cardiac tamponades. After a followup of 40.3 ± 17.3 months, 78.4% of patients were alive, with the annual mortality rate of 5.3%. Compared to the predicted risk, the observed incidence of thromboembolism was lower by 71%, and the bleeding incidence was lower by 69%. Conclusions: Percutaneous LAAO procedures can be safely performed by cardiac surgeons, with no cardiological assistance. LAAO done by surgeons is safe and effective, and periprocedural and long-term outcomes are excellent. Cardiac surgeons should be trained in both types of LAAO: endocardial and epicardial.

show abstract

“…Percutaneous left atrial appendage occlusion (LAAO) has emerged as an acceptable alternative treatment for patients with nonvalvular atrial fibrillation (NVAF) in whom oral anticoagulation (OAC) therapy is contraindicated or anticoagulation therapy is ineffective [1][2][3][4]. Con-sequently, the number of LAAO procedures has rapidly increased in recent years.…”

Section: Introductionmentioning

confidence: 99%

Long-term effect of anticoagulation following left atrial appendage occlusion with the LARIAT device in patients with nonvalvular atrial fibrillation: impact on thromboembolism, bleeding and mortality. Real life data

Litwinowicz¹,

Filip²,

Sobczyk³

et al. 2020

pwki

Self Cite

View full text Add to dashboard Cite

Introduction: Indications for left atrial appendage occlusion (LAAO) are varied and patients require individual management strategies. However, currently no guidelines exist for postprocedure oral anticoagulation (OAC) after an LAAO procedure.Aim: To evaluate the effect of OAC on thromboembolism, bleeding and mortality following the LAAO procedure for patients with AF.Material and methods: One hundred and thirty-nine consecutive patients with nonvalvular atrial fibrillation (NVAF) who underwent LAAO with the LARIAT device were followed for at least 40 months. Decisions about OAC and its modifications were individualized based on clinical presentation, patient and physician preferences.Results: Following LAAO, 52 (41%) patients did not receive OAC (No-OAC group) and 75 (59%) patients received OAC (OAC group), without any intergroup differences in CHADS 2 , CHA 2 DS 2 -VASc score or other thromboembolic risk factors. The median HAS-BLED score was higher in the OAC-group (median 3 (3-4) vs. 3 (2-4), p = 0.014). During a median follow-up time of 51 (43-57) vs. 55 (48-59) months in the No-OAC group and in the OAC group (p = 0.19) there were no significant differences between groups in ischemic stroke/TIA, 0 (0%) vs. 2 (2.7%), other thromboembolic events, 0 (0%) vs. 1 (1.3%), life-threatening, disabling or major events, 2 (3.7%) vs. 2 (2.7%), or annual mortality rate, 1.9% vs. 0.9%, respectively.Conclusions: There is no need for OAC after the LAAO procedure. Omitting OAC after an LAAO procedure in AF patients: (1) has similar stroke prevention rates as patients on OAC, (2) has similar bleeding prevention rates as patients on OAC, (3) has similar safety endpoints and long-term efficacy as patients on OAC.

show abstract

Percutaneous left atrial appendage closure using the LAmbre device. First clinical results in Poland

Cited by 11 publications

References 16 publications

Left Atrial Appendage Closure with a New Occluder Device: Efficacy, Safety and Mid-Term Performance

Left Atrial Appendage Closure with a New Occluder Device: Efficacy, Safety and Mid-Term Performance

Why should cardiac surgeons occlude the left atrial appendage percutaneously?

Long-term effect of anticoagulation following left atrial appendage occlusion with the LARIAT device in patients with nonvalvular atrial fibrillation: impact on thromboembolism, bleeding and mortality. Real life data

Contact Info

Product

Resources

About